Lorenzo Leoni

TiVenture SA is a venture capital fund with headquarters in Lugano, Switzerland. The firm was founded in 2012.

Elion Oncology, Inc. engages in the provision of pharmaceutical services. The company was founded in 2016 and is headquartered in Bethesda, MD.

GT Gain Therapeutics SA operates as a preclinical stage biotech firm developing a class of next generation brain-penetrant non-competitive pharmacological chaperones for the treatment of devastating diseases using the proprietary SEE-Tx technology. Its projects include Beta-galactosidase GLB1 gene and Glucosylceramidase GBA gene. The company was founded by Lorenzo Leoni and is headquartered in Lugano, Switzerland.

THERAMetrics holding AG is an independent biotech company, which discovers drugs for patients suffering from rare diseases. The company was founded by Fabio Cavalli, Vera Cavalli, Patrick Pozzorini, Dorian Bevec and Michael von und zu Liechtenstein on February 9, 2001 and is headquartered in Stans, Switzerland.

Salmedix, Inc. develops oncology and small molecule drugs to treat hematological malignancies. The company's product, Treanda, is currently in Phase II clinical trials in the United States and Canada for the treatment of indolent (slowly progressing) non-Hodgkin's lymphoma. It was founded in 2000 and is located in San Diego, CA.

UCSD Medical Center provides medical services to its clients. The medical center is a part of University of California, San Diego. UCSD Medical Center's facilities consist of UCSD Thornton Hospital in La Jolla, UCSD Medical Center in Hillcrest, and several specialty outpatient clinics and ambulatory health facilities throughout the area. The services provided by the medical center and its affiliates include general medicine and primary care, women's health services, and emergency care for the treatment of serious conditions. The company is headquartered in San Diego, CA

Telormedix SA operates as a biopharmaceutical company, that focuses on targeted immunity in the treatment of cancer and other diseases. Its products include TMX-101 for the treatment of localized bladder cancer, TMX-201 for the topical treatment of bladder cancer, skin cancer, and other indications, as well as for use as a vaccine adjuvant, and TMX-302 for use in preclinical trials for the treatment of autoimmune disease. The company was founded in October 2007 by Lorenzo Leoni, Roberto Maj, Rolf M. Zinkernagel and Dennis A. Carson and is headquartered in Lugano, Switzerland.